Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. - Wikidata - awgldk - TriplyDB

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.

http://www.wikidata.org/entity/Q34644974

about

Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties Non-clinical development of CER-001 HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis The role of the lymphatic system in cholesterol transport Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL New Era of Lipid-Lowering Drugs High-Density Lipoproteins: Nature's Multifunctional Nanoparticles Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?Cholesterol, inflammation and innate immunity Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings.Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I.Effects of LDL Receptor Modulation on Lymphatic Function Evolving targets for lipid-modifying therapy Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein HDL and CER-001 Inverse-Dose Dependent Inhibition of Atherosclerotic Plaque Formation in apoE-/- Mice: Evidence of ABCA1 Down-Regulation.Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial.Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.Invasive coronary imaging: any role in primary and secondary prevention?Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).The year in cardiology 2014: coronary intervention.Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance.High-density lipoprotein-based drug discovery for treatment of atherosclerosis.ApoA-I-Directed Therapies for the Management of Atherosclerosis.High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need.High-density lipoprotein mimetics: promises and challenges.HDL cholesterol: reappraisal of its clinical relevance.Synthetic High-Density Lipoprotein (sHDL) Inhibits Steroid Production in HAC15 Adrenal Cells Lipoproteins and lipoprotein mimetics for imaging and drug delivery.High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.Dietary Strategies and Novel Pharmaceutical Approaches Targeting Serum ApoA-I Metabolism: A Systematic Overview Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis.HDL Cholesterol Story Is Dead: Long Live HDL!Apolipoprotein A-I Modulates Atherosclerosis Through Lymphatic Vessel-Dependent Mechanisms in Mice.Reconstituted high-density lipoprotein therapies: a cause for optimism.

P2860

Q26738588-2DB379B9-1426-4252-8763-2D78E5049599 Q26750603-0C55612C-E795-43B5-A236-09E087BE9BB3 Q26779282-F5A37156-E93C-43CE-BC46-96AAFF49A4A5 Q26782972-8B3AE37A-EDFF-417E-AE63-EB637204F028 Q26782973-E823929B-D3AC-47BD-B259-6FB5DCFAA6F4 Q26801507-04407FFF-0757-445D-84C8-A80DE3C5D947 Q28072298-88A8B9B1-CA0F-4C37-A0A1-358BB1703C3C Q28077290-FB1981D4-AA05-48ED-8531-1750BB451E3F Q28080768-CCFA8F58-C8CA-477A-A7FC-A9E9357757D0 Q28086912-8C42FD2E-5D23-402E-9083-18D88AB22AC6 Q30364133-33E50B00-A3FE-4A0D-9D87-2CC67C2FA4DE Q33571579-A68B368A-B5E4-49EB-B8B0-B389B7B355AD Q33714672-CECC1D7A-BF07-45D0-8B3F-988CED1D8633 Q34238630-52554617-DA13-402F-AE7A-276F81AB35D3 Q34238652-C40EC39F-487E-42DC-9CC6-CDBC2C59785A Q34530204-3661D0B8-0ECB-4709-9974-503BA73A9429 Q34880292-830B25AD-8B55-46FB-A629-5FD5D0453ED3 Q35120961-1320D047-1DBA-421A-8B38-DE3DA1812501 Q35536400-CBCFCB5B-1C7B-47C9-AE61-9B1AD62ECACD Q35763571-575E156C-2EDE-49C9-9070-9E6AFEC07BDB Q35903590-116678B7-C885-414A-B8C8-9E06EC9838D1 Q36141666-2198F5C6-629A-44C6-BC05-6876D4F603E0 Q37030524-0F16BC6B-F727-4C29-9F2F-585839012128 Q37488452-F33E004A-045B-4517-BB0F-72B4BDC80461 Q38307432-A5C68769-9048-4E03-B87D-141CC690D885 Q38372740-773FC137-0B8C-4F5E-BEB2-863D23D9F16D Q38431166-43E1FAB0-F2AE-4E5F-97EE-AE6BDE5DBA53 Q38506490-DFB19751-18C9-4E45-92CF-7F07AC52B89B Q38579703-2AE0B29A-DE7D-4DC6-A19D-C4ECA9EBB1FF Q38624772-0B79D685-9017-4614-BEE0-DE4C42A75226 Q38650575-A8B0466C-CE8B-4EC0-9F78-DDA290E2A790 Q38739884-79CF2A82-2419-46F7-AB77-3049A7369A4C Q38767004-2B934867-D1A5-4C05-AE4E-3E1A984FC2D5 Q38822339-56B32534-D5F2-44C4-B781-43383263DB9A Q38965138-24F9A5F7-C01E-4BED-ACC0-17128B7FCCFE Q39427274-7F60F30B-45E8-475C-B6F7-3111BE159977 Q40535855-C4230FC0-0641-4518-A160-F0BF1BA0ED54 Q41640075-2529BB7A-188F-481C-BEF6-26D18E510CCB Q42373755-0715FED5-A21A-47D8-B4E6-CB04D758DB88 Q43096489-135A1EFE-8065-411C-84CE-62E761AE2E61

P2860

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.

http://www.wikidata.org/entity/Q34644974

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effects of the high-density li ...... syndromes: a randomized trial.

@ast

Effects of the high-density li ...... syndromes: a randomized trial.

@en

Effects of the high-density li ...... syndromes: a randomized trial.

@nl

type

label

Effects of the high-density li ...... syndromes: a randomized trial.

@ast

Effects of the high-density li ...... syndromes: a randomized trial.

@en

Effects of the high-density li ...... syndromes: a randomized trial.

@nl

prefLabel

Effects of the high-density li ...... syndromes: a randomized trial.

@ast

Effects of the high-density li ...... syndromes: a randomized trial.

@en

Effects of the high-density li ...... syndromes: a randomized trial.

@nl

P1433

Q34644974-87D093D7-FFA8-4DFF-B572-43257B1A245B

P1476

Q34644974-AF4CCF2E-B6B7-4E3E-BDFA-CC31F8C23A5C

P2093

Q34644974-0E79AB5F-413B-4C24-968C-232E5FD83713

Q34644974-19FA44E4-B3BE-4E63-8E88-F83E60190D09

Q34644974-34378E4F-B603-4B01-9846-63559756A104

Q34644974-362D8409-C304-40DE-B3F2-DB657BC7B71B

Q34644974-5D668935-039F-4590-B1EB-5DCCFBB66BBD

Q34644974-62D71FF9-E67A-4120-9004-BAC0465704E2

Q34644974-7A87C8AF-EB14-4941-8D00-521ABD6EDABC

Q34644974-7B1CA058-BA83-4D99-A4CE-9DE7AF90D233

Q34644974-7DFA4643-F065-44B5-BCAF-6B1C9A2F4BAE

Q34644974-7F4ECA4F-5779-4A21-BC12-92200A2B9731

P2860

Q34644974-009ECBF8-1AA1-4884-B28A-3C7DF4449172

Q34644974-063621D1-BDEF-43CC-A024-2B10C01700D1

Q34644974-0EB23CDE-CAE6-48C8-B26E-7793C3B9EEAC

Q34644974-1B95F82E-0EAB-4E2B-887E-F2B1E9E55E50

Q34644974-2505A2F3-DA2E-4810-9804-1142EB272718

Q34644974-42DCA842-B81A-4E1F-B305-63A5B1CD7888

Q34644974-523564AC-EE27-42A8-9E69-FC6E700CF3A5

Q34644974-5A2049B6-12B8-47F5-8982-3BC881C15543

Q34644974-5D48BD2F-5277-44F8-A7CF-8672540CB1FD

Q34644974-7CEEC1C5-5352-418B-BD65-78FCDA0AB1E3

P304

Q34644974-FCA5D9DA-5A46-4E74-90E3-2F4C5E0DF777

P31

Q34644974-7A9DF664-DBC9-408F-9351-D28C3C250CF1

P356

Q34644974-FB596BBE-5C0C-42A2-B15C-78B03E741CFB

P433

Q34644974-B616391A-459C-49C1-9359-819AE14FF68F

P478

Q34644974-F8A301BF-38E4-41F2-A35C-7F37EE0118C5

P50

Q34644974-3C4D0DF9-DC67-41FC-9CB9-A8C1E9CA4BA4

Q34644974-5AC3134A-3CE5-47CE-BAB5-E4957D8AB18A

P577

Q34644974-29AAA26B-00EF-43C8-9886-CD724B3FAC7F

P5875

Q34644974-3C135021-18C1-4BD8-A9CE-E990888C6070

P698

Q34644974-273C2B43-A145-4E49-81AA-C27BBEB6C49A

P921

Q34644974-29B4474F-45C2-442C-B3E0-55901B95049E

Q34644974-E0110BFA-E489-41A5-A0AA-F47DED442F39

Q34644974-FD955DE0-D8D7-41F1-82A8-2894E318ADFD

P932

Q34644974-41B8DABD-1F04-43B7-A616-072F903F97BB

P356

P1433

European Heart Journal

P1476

Effects of the high-density li ...... syndromes: a randomized trial.

@en

P2093

Ahmed Tawakol

http://www.w3.org/2001/XMLSchema#string

Can HDL Infusions Significantl ...... ion (CHI-SQUARE) Investigators

http://www.w3.org/2001/XMLSchema#string

Christie M Ballantyne

http://www.w3.org/2001/XMLSchema#string

Constance Keyserling

http://www.w3.org/2001/XMLSchema#string

David D Waters

http://www.w3.org/2001/XMLSchema#string

Heather Klepp

http://www.w3.org/2001/XMLSchema#string

Jacques Lespérance

http://www.w3.org/2001/XMLSchema#string

Jean-Claude Tardif

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Dasseux

http://www.w3.org/2001/XMLSchema#string

John F Paolini

http://www.w3.org/2001/XMLSchema#string

P2860

The state of US health, 1990-2010: burden of diseases, injuries, and risk factors

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Effects of torcetrapib in patients at high risk for coronary events

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells.

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

P304

3277-3286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHU171

http://www.w3.org/2001/XMLSchema#string

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang Koenig

Thomas Lüscher

P577

2014-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262000737

http://www.w3.org/2001/XMLSchema#string

P698

24780501

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4258222

http://www.w3.org/2001/XMLSchema#string